Skip to main content
Top
Published in: BMC Cancer 1/2005

Open Access 01-12-2005 | Research article

A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy

Authors: L Lim, P Gibbs, D Yip, JD Shapiro, R Dowling, D Smith, A Little, W Bailey, M Liechtenstein

Published in: BMC Cancer | Issue 1/2005

Login to get access

Abstract

Background

To prospectively evaluate the efficacy and safety of selective internal radiation (SIR) spheres in patients with inoperable liver metastases from colorectal cancer who have failed 5FU based chemotherapy.

Methods

Patients were prospectively enrolled at three Australian centres. All patients had previously received 5-FU based chemotherapy for metastatic colorectal cancer. Patients were ECOG 0–2 and had liver dominant or liver only disease. Concurrent 5-FU was given at investigator discretion.

Results

Thirty patients were treated between January 2002 and March 2004. As of July 2004 the median follow-up is 18.3 months. Median patient age was 61.7 years (range 36 – 77). Twenty-nine patients are evaluable for toxicity and response. There were 10 partial responses (33%), with the median duration of response being 8.3 months (range 2–18) and median time to progression of 5.3 mths. Response rates were lower (21%) and progression free survival shorter (3.9 mths) in patients that had received all standard chemotherapy options (n = 14). No responses were seen in patients with a poor performance status (n = 3) or extrahepatic disease (n = 6). Overall treatment related toxicity was acceptable, however significant late toxicity included 4 cases of gastric ulceration.

Conclusion

In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity. Further studies are required to better define the subsets of patients most likely to respond.
Appendix
Available only for authorised users
Literature
1.
go back to reference Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR): Cancer in Australia 2000. 2003, Canberra: AIHW Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR): Cancer in Australia 2000. 2003, Canberra: AIHW
2.
go back to reference Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83: 18-29. 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M.CrossRefPubMed Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83: 18-29. 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M.CrossRefPubMed
3.
go back to reference Weiss L, Grundmann E, Torhorst J, Harveit F, Moberg I, Eder M, Fenoglio-Preiser C, Napier J, et al: Haematogenous Metastasis patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol. 1986, 150: 195-203. 10.1002/path.1711500308.CrossRefPubMed Weiss L, Grundmann E, Torhorst J, Harveit F, Moberg I, Eder M, Fenoglio-Preiser C, Napier J, et al: Haematogenous Metastasis patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol. 1986, 150: 195-203. 10.1002/path.1711500308.CrossRefPubMed
4.
go back to reference Ingold JA, Reed GB, Kaplan HS, Bagshaw MA: Radiation hepatitis. AM J Roentgenol Radium Ther Nucl Med. 1965, 03: 200-208. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA: Radiation hepatitis. AM J Roentgenol Radium Ther Nucl Med. 1965, 03: 200-208.
5.
go back to reference Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995, 31: 1237-48. 10.1016/0360-3016(94)00418-K.CrossRefPubMed Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995, 31: 1237-48. 10.1016/0360-3016(94)00418-K.CrossRefPubMed
6.
go back to reference Gray BN, Anderson JE, Burton MA, van Hazel G, Codde J, Morgan C, et al: Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992, 62: 105-10.CrossRefPubMed Gray BN, Anderson JE, Burton MA, van Hazel G, Codde J, Morgan C, et al: Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992, 62: 105-10.CrossRefPubMed
7.
go back to reference Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001, 12: 1711-20. 10.1023/A:1013569329846.CrossRefPubMed Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001, 12: 1711-20. 10.1023/A:1013569329846.CrossRefPubMed
8.
go back to reference Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK: Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998, 40: 583-92. 10.1016/S0360-3016(97)00818-3.CrossRefPubMed Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK: Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998, 40: 583-92. 10.1016/S0360-3016(97)00818-3.CrossRefPubMed
9.
go back to reference Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M: A prospective study of treatment with Selective Internal Radiation Therapy (SIR spheres) in patients with unresectable primary or secondary hepatic malignancies. Internal Medicine Journal. (in press-to be published in April 2005 edition of Internal Medicine Journal) Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M: A prospective study of treatment with Selective Internal Radiation Therapy (SIR spheres) in patients with unresectable primary or secondary hepatic malignancies. Internal Medicine Journal. (in press-to be published in April 2005 edition of Internal Medicine Journal)
10.
go back to reference Rougier P, Van Custem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998, 352: 1407-1412. 10.1016/S0140-6736(98)03085-2.CrossRefPubMed Rougier P, Van Custem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998, 352: 1407-1412. 10.1016/S0140-6736(98)03085-2.CrossRefPubMed
11.
go back to reference Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol. 2003, 21: 2059-2069. 10.1200/JCO.2003.11.126.CrossRefPubMed Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol. 2003, 21: 2059-2069. 10.1200/JCO.2003.11.126.CrossRefPubMed
12.
go back to reference Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351: 337-45. 10.1056/NEJMoa033025.CrossRefPubMed Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351: 337-45. 10.1056/NEJMoa033025.CrossRefPubMed
13.
go back to reference Saltz L, Meropol NJ, Loehrer PJ, Needle M, Kopit J, Mayer RJ: Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. J Clin Oncol. 2004, 22: 1201-1208. 10.1200/JCO.2004.10.182.CrossRefPubMed Saltz L, Meropol NJ, Loehrer PJ, Needle M, Kopit J, Mayer RJ: Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. J Clin Oncol. 2004, 22: 1201-1208. 10.1200/JCO.2004.10.182.CrossRefPubMed
14.
go back to reference Stubbs RS, Cannan RJ, Mitchell AW: Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001, 5: 294-302. 10.1016/S1091-255X(01)80051-2.CrossRefPubMed Stubbs RS, Cannan RJ, Mitchell AW: Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001, 5: 294-302. 10.1016/S1091-255X(01)80051-2.CrossRefPubMed
16.
go back to reference Scrag D: The price tag on progress chemotherapy for colorectal cancer. N Engl J Med. 2004, 351 (4): 317-9. 10.1056/NEJMp048143.CrossRef Scrag D: The price tag on progress chemotherapy for colorectal cancer. N Engl J Med. 2004, 351 (4): 317-9. 10.1056/NEJMp048143.CrossRef
Metadata
Title
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy
Authors
L Lim
P Gibbs
D Yip
JD Shapiro
R Dowling
D Smith
A Little
W Bailey
M Liechtenstein
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2005
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-5-132

Other articles of this Issue 1/2005

BMC Cancer 1/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine